Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir /- ribavirin for hepatitis C genotype 1-final results of the REV1TAL study

John Lubel; Simone Strasser; Katherine A Stuart; Gregory Dore; Alexander Thompson; Stephen Pianko; Steven Bollipo; Joanne L Mitchell; Vincenzo Fragomeli; Tracey Jones; Sarah Chivers; Paul Gow; David Iser; Miriam Levy; Edmund Tse; Alessia Gazzola; Wendy Cheng; Saroj Nazareth; Sam Galhenage; Amanda Wade; Martin Weltman; Alan Wigg; Gerry MacQuillan; Joe Sasadeusz; Jacob George; Amany Zekry; Stuart K Roberts

Journal article

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir /- ribavirin for hepatitis C genotype 1-final results of the REV1TAL study

John Lubel, Simone Strasser, Katherine A Stuart, Gregory Dore, Alexander Thompson, Stephen Pianko, Steven Bollipo, Joanne L Mitchell, Vincenzo Fragomeli, Tracey Jones, Sarah Chivers, Paul Gow, David Iser, Miriam Levy, Edmund Tse, Alessia Gazzola, Wendy Cheng, Saroj Nazareth, Sam Galhenage, Amanda Wade Show all

Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2017

DOI: 10.3851/IMP3168

University of Melbourne Researchers

Paul Gow Author Medicine - Austin Health

Alex Thompson Author Medicine - St Vincent's Hospital

Joseph Sasadeusz Author Doherty Institute

Grants

Funding Acknowledgements

AbbVie provided drug for patients included in the Compassionate Program and provided funding for the research through an unrestricted grant administered by the Gastroenterological Society of Australia. AbbVie was not involved in the data collection related to this publication. Upon study completion, AbbVie was provided a copy of the publication for the purposes of performing an accuracy review and as a part of routine safety monitoring of patients treated with Viekira Pak (Viekirax)/Exviera.